RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
ARA-290, also called cibinetide, is a synthetic peptide investigated for its effects on tissue-protection signaling and small nerve fibers. Its development grew from research into erythropoietin, a protein involved in red blood cell production that also has tissue-protective activity in experimental models. Early human studies have examined neuropathy associated with sarcoidosis and type 2 diabetes. Some findings suggest biological activity, but improvements have varied across measurements and study groups. These results support further investigation rather than broad claims about nerve regeneration, pain relief, or safety. [1–4]
WHAT IS ARA-290?
ARA-290 is an 11-amino-acid peptide designed using the three-dimensional structure of part of erythropoietin, commonly abbreviated EPO. It is much smaller than the complete EPO protein. Researchers developed this approach to investigate tissue-protective effects separately from the stimulation of red blood cell production. [1]
The foundational research described peptides modeled on the exposed surface of EPO’s helix B region. The term “nonerythropoietic” refers to the absence of red-blood-cell-stimulating activity in the systems tested. It does not mean that a compound is free of other biological effects or potential risks. [1]
WHY HAVE RESEARCHERS STUDIED SMALL NERVE FIBERS?
Small nerve fibers help carry temperature and pain signals and contribute to automatic functions such as sweating. Damage to these fibers can produce symptoms that differ considerably between people. Research therefore uses several kinds of measurements, including questionnaires, sensory testing, skin samples, and imaging of nerves in the cornea, the clear surface at the front of the eye. [2,3]
These measurements answer different questions. A change in a symptom questionnaire is not the same finding as a change in nerve structure, and neither alone demonstrates recovery across the nervous system.
WHAT DID THE EARLY SARCOIDOSIS STUDY FIND?
A 2012 randomized, double-blind pilot study reported results from 22 participants with sarcoidosis and symptoms of small fiber neuropathy. After four weeks, the ARA-290 group showed greater improvement than placebo on a questionnaire covering small fiber neuropathy symptoms. [2]
However, pain intensity measured with the Brief Pain Inventory and fatigue improved similarly in both groups. The study therefore did not establish superiority over placebo for those outcomes. Its small size and limitations in confirming small fiber neuropathy also restricted how confidently the results could be interpreted. [2]
WHAT DID THE LARGER CIBINETIDE TRIAL SHOW?
A 2017 phase 2b trial randomized 64 participants with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Its main endpoint was change in corneal nerve fiber area after 28 days. One of the three cibinetide groups showed a statistically significant improvement compared with placebo; the other two did not. A skin marker associated with nerve growth also increased in the group with the significant corneal result. [3]
Pain improved in all groups. Although the researchers described a potentially meaningful pain reduction in a subgroup, that comparison did not reach statistical significance. The findings provided evidence of changes in nerve-related measurements, but did not establish reliable pain relief or lasting restoration of nerve function. [3]
WHAT HAS BEEN STUDIED IN TYPE 2 DIABETES?
A separate randomized, placebo-controlled study enrolled 49 participants with type 2 diabetes and painful neuropathy, with 48 included in the analysis. Researchers reported improvements in the PainDetect questionnaire and selected metabolic measurements, including HbA1c, a marker of blood glucose exposure. Other symptom scales did not show the same pattern of benefit. [4]
Corneal nerve fiber density did not improve significantly across the full ARA-290 group. An exploratory analysis found an increase from baseline among participants whose initial density was below the normal range. Because this subgroup analysis was performed after the main analysis, it requires confirmation rather than being treated as definitive evidence. [4]
WHAT REMAINS UNCERTAIN?
These trials were small and assessed relatively short periods. Longer studies would be needed to establish whether observed changes persist and translate into meaningful functional improvements. Several investigators also disclosed relationships with the compound’s developer, making independent replication particularly valuable. [2,3]
Safety cannot be inferred from the peptide’s design. Serious adverse events occurred in the diabetes trial, and the report discussed differing assessments of their relationship to treatment. Such events do not by themselves establish causation, but the findings should not be summarized as proof that ARA-290 is risk-free. [4]
Published studies concern specific study materials, participants, and controlled research conditions. They do not establish that a separately supplied research product has equivalent identity, purity, formulation, or biological performance.
REFERENCES
Some study titles are shortened for readability. Each link identifies the original source.
[1] Brines M, Patel NSA, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences. 2008;105(31):10925–10930.
https://doi.org/10.1073/pnas.0805594105
[2] Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine. 2012;18:1430–1436.
https://doi.org/10.2119/molmed.2012.00332
[3] Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Investigative Ophthalmology & Visual Science. 2017;58(6):BIO52–BIO60.
https://doi.org/10.1167/iovs.16-21291
[4] Brines M, Dunne AN, van Velzen M, et al. ARA 290 and metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2014;20:658–666.
https://doi.org/10.2119/molmed.2014.00215